Companies Dominating the Head and Neck Squamous Cell Carcinoma (HNSCC) Landscape
- Immutep Limited
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Novartis AG
- Fortress Biotech, Inc.
- F. Hoffmann-La Roche Ltd
- Eli Lilly and Company
- Bristol Myers Squibb Company
- AstraZeneca PLC
- Pfizer Inc.
- Boehringer Ingelheim International GmbH
- Checkpoint Therapeutics, Inc.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
2025 Head and Neck Squamous Cell Carcinoma Market is evaluated at USD 2.53 billion.
The global head and neck squamous cell carcinoma market size was worth over USD 2.37 billion in 2024 and is anticipated to see a CAGR exceeding 8.7%, reaching over USD 7.01 billion by 2037.
North America is expected to grow to USD 3.65 billion by 2037, driven by a high ratio of alcohol and tobacco consumption, as well as strong healthcare infrastructure in the region.
The major players in the market include Immutep Limited, Novartis AG, Fortress Biotech, Inc., F. Hoffmann-La Roche Ltd, Eli Lilly and Company, Bristol Myers Squibb Company, AstraZeneca PLC, Pfizer Inc., Boehringer Ingelheim International GmbH, Checkpoint Therapeutics, Inc.
